In HCC, it exerts its anti-tumor effects via a dual mechanism: classically, by impairing 28S rRNA methylation, and non-classically, by inhibiting the phosphorylation of the mTOR pathway effector 4EBP1 [139]. Here, MTOR is linked to neoplasm.